Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

scientific article

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1014987844
P356DOI10.1007/S00228-008-0481-Y
P698PubMed publication ID18751690
P5875ResearchGate publication ID23218336

P50authorHelen McIlleronQ48287171
Karen CohenQ55446317
Ulrika S H SimonssonQ73506261
P2093author name stringPeter Smith
Britt Jansson
Doaa Elsherbiny
P2860cites workIncreasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministrationQ83202534
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4Q28293310
The growing burden of tuberculosis: global trends and interactions with the HIV epidemicQ29616520
HIV-TB co-infection: epidemiology, diagnosis & management.Q30350510
Chronopharmacokinetics: implications for drug treatmentQ33742389
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsQ33975889
Body composition and nutritional parameters in HIV and AIDS patientsQ35054960
Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction.Q35620036
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individualsQ35804046
Pharmacokinetics of nevirapine: initial single-rising-dose study in humansQ35808226
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancyQ35827891
Nevirapine in the treatment of HIV.Q35917412
Practical guidelines to interpret plasma concentrations of antiretroviral drugsQ35929973
Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivityQ36070790
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infectionQ37361492
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug deliveryQ40923441
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsQ42627921
Regulation of the human CYP2B6 gene by the nuclear pregnane X receptorQ43705734
An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasmaQ43756284
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosisQ43824019
Stability and performance of a population pharmacokinetic modelQ43868861
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected populationQ44469967
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patientsQ44787744
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitorsQ44905262
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individualsQ45428802
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replicationQ45764043
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosisQ46838565
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosisQ46906469
Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilateQ46925759
In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agentsQ48497171
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.Q54408488
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450Q73201582
Effect of tuberculosis therapy on nevirapine trough plasma concentrationsQ73271834
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteersQ73508511
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arraysQ77198790
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMQ77296898
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosisQ79402194
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicinQ79738909
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaborationQ80124577
P433issue1
P921main subjectSouth AfricaQ258
tuberculosisQ12204
nevirapineQ263713
pharmacokineticsQ323936
chemotherapyQ974135
P304page(s)71-80
P577publication date2008-08-27
P1433published inEuropean Journal of Clinical PharmacologyQ1376707
P1476titlePopulation pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients
P478volume65

Reverse relations

cites work (P2860)
Q33839294Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment
Q36905884Clinical pharmacokinetics of antiretroviral drugs in older persons
Q24609011Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all
Q37509532Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
Q34212799Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the
Q34149022Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics
Q37666456Management of individuals requiring antiretroviral therapy and TB treatment
Q38720418Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group
Q36276839Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience
Q34405883Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
Q24631021Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams
Q38865904Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns
Q24602072Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients
Q40736787Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach
Q35598505Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
Q38207924Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins

Search more.